Interferon-β treatment and the natural history of relapsing-remitting multiple sclerosis [3]

Annals of Neurology

Volumn 63, Issue 1, 2008, Pages 125-126

  Koch, Marcus ^a   Mostert, Jop ^a   De Keyser, Jacques ^a   Tremlett, Helen ^b   Filippini, Graziella ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

DISEASE COURSE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; LETTER; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; COMORBIDITY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; RECURRENCE; REPRODUCIBILITY OF RESULTS; SELECTION BIAS; WITHHOLDING TREATMENT;

EID: 39049140800     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21185     Document Type: Letter

References (4)

1. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-306.
2. Ebers G. Disease evolution in multiple sclerosis. J Neurol 2006; 253(suppl 6):vi3-vi8.
3. Kremenchutzky M, Rice G, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006;129:584-594.
4. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450-457.